- Trials with a EudraCT protocol (151)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
151 result(s) found for: Shock therapy.
Displaying page 1 of 8.
EudraCT Number: 2020-004881-20 | Sponsor Protocol Number: NORDIST | Start Date*: 2021-10-18 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:AZIENDA USL TOSCANA SUD EST Sezione di Arezzo | ||||||||||||||||||||||||||||||||||||||
Full Title: Comparison of norepinephrine and dobutamine in patients in cardiogenic shock | ||||||||||||||||||||||||||||||||||||||
Medical condition: Patients over 18 years of age with cardiogenic shock | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: IT (Trial now transitioned) | ||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001613-33 | Sponsor Protocol Number: IgM-FAT | Start Date*: 2019-04-18 | |||||||||||||||||||||
Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA DI MODENA | |||||||||||||||||||||||
Full Title: Efficacy and safety of adjunctive IgM-enriched immunoglobulin therapy with a personalized dose based on serum IgM-titers vs. standard dose in patients with septic shock. A multicenter, intervention... | |||||||||||||||||||||||
Medical condition: Septic shock | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003158-10 | Sponsor Protocol Number: GI-CCT372273 | Start Date*: 2014-04-11 | |||||||||||
Sponsor Name:The George Institute for Global Health | |||||||||||||
Full Title: ADRENAL- ADjunctive coRticosteroid trEatment iN criticAlly ilL patients with septic shock. | |||||||||||||
Medical condition: Septic Shock | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DK (Completed) IE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000504-92 | Sponsor Protocol Number: APX-PHP-07-008 | Start Date*: 2009-09-02 | |||||||||||
Sponsor Name:Apex Bioscience, Inc. | |||||||||||||
Full Title: PHP for the Treatment of Excess Nitric Oxide in Distributive Shock (PHOENIX) | |||||||||||||
Medical condition: Catecholamine-resistant distributive shock | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended) BE (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000427-27 | Sponsor Protocol Number: VIPER-SHOCK | Start Date*: 2017-03-30 | |||||||||||
Sponsor Name:Section for Transfusion Medicine, Capitol Region Blood Bank | |||||||||||||
Full Title: Vasculopathic Injury and Plasma as Endothelial Rescue in septic shock (SHOCK) trial | |||||||||||||
Medical condition: Patients with septic shock admitted to the intensive care unit. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005363-24 | Sponsor Protocol Number: CRO1888 | Start Date*: 2012-12-05 | |||||||||||
Sponsor Name:Imperial College London | |||||||||||||
Full Title: Vasopressin vs Noradrenaline as Initial therapy in Septic Shock | |||||||||||||
Medical condition: Septic Shock | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005441-38 | Sponsor Protocol Number: F1K-MC-EVDP | Start Date*: 2008-03-07 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients with Septic Shock | |||||||||||||
Medical condition: Septic shock | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) NL (Completed) FR (Completed) BE (Completed) IT (Completed) PT (Completed) FI (Completed) CZ (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003973-41 | Sponsor Protocol Number: 000133 | Start Date*: 2015-06-22 | |||||||||||
Sponsor Name:Ferring Pharmaceuticals A/S | |||||||||||||
Full Title: A Double-blind, Randomised, Placebo-controlled, Phase 2b/3 Adaptive Clinical Trial Investigating the Efficacy and Safety of Selepressin as Treatment for Patients with Vasopressor-dependent Septic S... | |||||||||||||
Medical condition: Vasopressor-dependent Septic Shock | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) NL (Completed) FR (Completed) DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000707-81 | Sponsor Protocol Number: VIPER-SEPSIS | Start Date*: 2016-04-26 | |||||||||||
Sponsor Name:Section for Transfusion Medicine, Capitol Region Blood Bank | |||||||||||||
Full Title: Vasculopathic Injury and Plasma as Endothelial Rescue in septic shock (SEPSIS) trial | |||||||||||||
Medical condition: Patients with septic shock admitted to the intensive care unit | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001131-31 | Sponsor Protocol Number: COMBAT-SHINE | Start Date*: 2019-06-25 | |||||||||||
Sponsor Name:Section for transfusion Medicines, Capital Region Blood Bank, Copenhagen University Hospital | |||||||||||||
Full Title: “Efficacy and safety of 72-hour infusion of Prostacyclin (1 ng/kg/min) in patients with septic shock induced endotheliopathy – a multicentre randomized, placebo-controlled, blinded, investigator-in... | |||||||||||||
Medical condition: Shock-induced endotheliopathy in patients with septic shock | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002440-41 | Sponsor Protocol Number: CO-ILEPSS | Start Date*: 2014-08-14 | |||||||||||
Sponsor Name:Rigshospitalet, Capital Region Bloodbank 2034, Section for Transfusion Medicine | |||||||||||||
Full Title: Safety and efficacy of iloprost and eptifibatide co-administration compared to standard therapy in patients with septic shock – a randomized, controlled, double-blind investigator-initiated trial | |||||||||||||
Medical condition: Septic shock | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004319-29 | Sponsor Protocol Number: P170914J | Start Date*: 2021-10-04 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: " LEVOSIMENDAN to facilitate weaning from ECMO in severe cardiogenic shock patients | |||||||||||||
Medical condition: Adult patients with acute cardiogenic shock refractory to conventional therapy placed on VA-ECMO support and for whom withdrawal from ECMO is possible. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-005687-27 | Sponsor Protocol Number: TAK-242_301 | Start Date*: 2008-08-06 | ||||||||||||||||
Sponsor Name:Takeda Global Research & Development Centre (Europe), Ltd. [...] | ||||||||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of TAK-242 Versus Placebo in Subjects With Sepsis Induced Cardiovascular and Respiratory Failure | ||||||||||||||||||
Medical condition: Septic shock and respiratory failure. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) BE (Completed) FI (Completed) CZ (Prematurely Ended) HU (Prematurely Ended) FR (Completed) AT (Prematurely Ended) NL (Prematurely Ended) SE (Prematurely Ended) DE (Prematurely Ended) ES (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2022-001949-20 | Sponsor Protocol Number: 1.0 | Start Date*: 2023-01-09 | |||||||||||
Sponsor Name:ALBIMMUNE S.L. | |||||||||||||
Full Title: Human albumin treatment in adult septic shock. A phase 2, multicenter, randomized, controlled study evaluating the immune response and organ failure. | |||||||||||||
Medical condition: Septic Shock | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-006445-41 | Sponsor Protocol Number: CTSSTS1010207V2 | Start Date*: 2012-01-28 | |||||||||||
Sponsor Name:HEALTH RICERCAE SVILUPPO SRL | |||||||||||||
Full Title: The irreversibility of hemorrhagic shock treatment with anti-opiod neuropeptide | |||||||||||||
Medical condition: Mortality of hemorrhagic shock grade 2 and 3 is from 50 to '80% in the first 24 hours, and morbidity and mortality betrayed is to 7 to 8 days of' 90% for Acute Respiratory Distress Syndrome and / o... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-005159-18 | Sponsor Protocol Number: CRO2047 | Start Date*: 2013-08-28 | ||||||||||||||||
Sponsor Name:Imperial College, London | ||||||||||||||||||
Full Title: An efficacy and mechanism evaluation study of Levosimendan for the Prevention of Acute oRgan Dysfunction in Sepsis (LeoPARDS) | ||||||||||||||||||
Medical condition: Septic shock. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-001788-34 | Sponsor Protocol Number: 15167 | Start Date*: 2018-02-23 | |||||||||||||||||||||
Sponsor Name:University Hospital Aachen, AöR, Dean of the Medical Faculty of the RWTH Aachen for the Managing Board of the University | |||||||||||||||||||||||
Full Title: Prospective, randomized study concerning personalized medicine with Pentaglobin® after interventional infectious source control in peritonitis patients | |||||||||||||||||||||||
Medical condition: Investigation of Pentaglobin® therapy in patients with sepsis and/or septic shock triggered by peritonitis after surgical infectious source control and simultaneous administration of antibiotics. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005756-37 | Sponsor Protocol Number: CONTENTSS | Start Date*: 2021-11-02 | ||||||||||||||||
Sponsor Name:Fundación Pública Andaluza para la Gestión de la | ||||||||||||||||||
Full Title: Double blind randomized clinical trial comparing noradrenaline plus placebo versus noradrenaline plus terlipressin in septic shock | ||||||||||||||||||
Medical condition: Patients with septic shock who remain without reaching the hemodynamic goal of TAM> 65 mmHg, despite volume replacement and administration of noradrenaline at doses equal to or greater than 0.2 μg ... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001785-14 | Sponsor Protocol Number: STRESS-L | Start Date*: 2017-11-09 | ||||||||||||||||
Sponsor Name:University Hospitals Birmingham NHS Foundation Trust | ||||||||||||||||||
Full Title: STRESS-L: STudy into the REversal of Septic Shock with Landiolol (Beta Blockade) | ||||||||||||||||||
Medical condition: Tachycardia in Septic Shock | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003496-36 | Sponsor Protocol Number: 69HCL17_0843 | Start Date*: 2019-11-06 | ||||||||||||||||
Sponsor Name:Hospices Civils de Lyon | ||||||||||||||||||
Full Title: Dosage optimization of piperacillin/tazobactam in ICU patients based on therapeutic drug monitoring of amikacin - OPTIMA | ||||||||||||||||||
Medical condition: sepsis or septic shock | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
